Plaintiff's law firm issued a press release on December 21, 2018, announcing the filing of the lawsuit. According to the press release, the Complaint alleges that, during the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts. Specifically, the Complaint alleges that throughout the Class Period Allergan concealed from investors the fact that the Company's CE Mark for its textured breast implants and tissue expanders was expiring in Europe.
Allergan plc Securities Litigation (2018)
Dec 23, 2018 | Allergan plc. NYSE: AGN | Case Status: Filed
If you purchased a significant amount of shares of Allergan plc. (NYSE: AGN), you have certain options. Investors should contact us.
Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Allergan plc.
First Identified Complaint
Thomas F. Cook, et al. v. Allergan plc, et al.
First Identified Complaint Filings
|#||Document Title||Filing Date|
|1||Complaint for Violations of the Federal Securities Laws||December 21st, 2018|
|2||U.S. District Court Civil Docket||December 21st, 2018|